CLINICAL RESEARCH: HEART FAILURE
Pre-Transplant Toxoplasma gondii Seropositivity Among Heart Transplant Recipients Is Associated With an Increased Risk of All-Cause and Cardiac Mortality
Satish Arora, MD*,*,
Pål A. Jenum, MD, PhD ,||,
Pål Aukrust, MD, PhD ,
Halvor Rollag, MD, PhD ,¶,
Arne K. Andreassen, MD, PhD*,
Svein Simonsen, MD, PhD*,
Einar Gude, MD*,
Arnt E. Fiane, MD, PhD ,
Odd Geiran, MD, PhD ,¶ and
Lars Gullestad, MD, PhD*
* Department of Cardiology, Rikshospitalet-Radiumhospitalet Medical Center, Oslo, Norway
Institute of Medical Microbiology, Rikshospitalet-Radiumhospitalet Medical Center, Oslo, Norway
Section of Clinical Immunology and Infectious Diseases, Rikshospitalet-Radiumhospitalet Medical Center, Oslo, Norway
Department of Thoracic and Cardiovascular Surgery, Rikshospitalet-Radiumhospitalet Medical Center, Oslo, Norway
|| Department of Microbiology, Central Laboratory, Hospital of Asker and Baerum, Oslo, Norway
¶ Faculty Division Rikshospitalet, University of Oslo, Oslo, Norway.
Manuscript received April 10, 2007;
revised manuscript received June 22, 2007,
accepted July 30, 2007.
* Reprint requests and correspondence: Dr. Satish Arora, Department of Cardiology, Rikshospitalet-Radiumhospitalet Medical Center, N-0027 Oslo, Norway. (Email: satish.arora{at}medisin.uio.no).
Objectives: We evaluated the risk of mortality, development of cardiac allograft vasculopathy (CAV), and acute cellular rejection among Toxoplasma gondii (T. gondii) seropositive heart transplant (HTx) recipients and the 4 donor/recipient seropairing groups.
Background: Chronic T. gondii infection is known to trigger potentially adverse immunoregulatory changes, but the long-term implication for HTx recipients has not been assessed previously.
Methods: Frozen pre-HTx serum samples of 288 recipients and 246 donors were evaluated for T. gondii serostatus using Platelia immunoglobulin G immunoassay. Patients had undergone prospective serotesting using alternative assays, and results determined by the 2 methods were compared. Data regarding mortality, CAV, and acute cellular rejection were available for all patients.
Results: Overall, 211 recipients (73%) were seronegative and 77 (27%) were seropositive. In total, 82 recipients died, 76 developed CAV, and 82 had 1 or more episode of treated cellular rejection. Recipient seropositivity was associated with a significantly higher risk of all-cause (hazard ratio [HR] 1.9, 95% confidence interval [CI] 1.1 to 3.4; p = 0.02) and CAV mortality (HR 4.4, 95% CI 1.3 to 15.6; p = 0.02) and a higher risk of developing advanced CAV (HR 2.7, 95% CI 1.2 to 5.8; p = 0.01). Seropositivity did not influence the number of rejection episodes, and donor/recipient seropairing was not a risk factor for any end point.
Conclusions: T. gondii seropositivity among HTx recipients is associated with an increased risk of all-cause and CAV mortality and of development of advanced CAV. This may be mediated via immunoregulatory changes triggered by chronic T. gondii infection and needs to be explored further.
|
Abbreviations and Acronyms
| | CAV = cardiac allograft vasculopathy | | CMV = cytomegalovirus | | EIA = enzyme immunoassay | | HTx = heart transplant/transplantation | | IFN = interferon | | IL = interleukin | | R = recipient | | T. gondii
= Toxoplasma gondii |
|
This article has been cited by other articles:

|
 |

|
 |
 
B. Hebraud, N. Kamar, J.-S. Borde, M.-H. Bessieres, M. Galinier, and L. Rostaing
Unusual presentation of primary toxoplasmosis infection in a kidney-transplant patient complicated by an acute left-ventricular failure
Clinical Kidney Journal,
December 1, 2008;
1(6):
429 - 432.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
X. Flores-Rios, M. J. Paniagua-Martin, J. Muniz-Garcia, and M. G. Crespo-Leiro
Pre-Transplant Toxoplasma gondii Seropositivity Among Heart Transplant Recipients and Mortality
J. Am. Coll. Cardiol.,
May 6, 2008;
51(18):
1827 - 1827.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Arora, P. A. Jenum, P. Aukrust, H. Rollag, A. K. Andreassen, S. Simonsen, E. Gude, A. E. Fiane, O. Geiran, and L. Gullestad
Reply
J. Am. Coll. Cardiol.,
May 6, 2008;
51(18):
1827 - 1828.
[Full Text]
[PDF]
|
 |
|
|